Fintel reports that on December 1, 2025, Jones Trading upgraded their outlook for Spyre Therapeutics (NasdaqGS:SYRE) from Hold to Buy.
Analyst Price Forecast Suggests 78.96% Upside
As of November 17, 2025, the average one-year price target for Spyre Therapeutics is $53.69/share. The forecasts range from a low of $21.21 to a high of $73.50. The average price target represents an increase of 78.96% from its latest reported closing price of $30.00 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Spyre Therapeutics is 0MM, a decrease of NaN%. The projected annual non-GAAP EPS is -3.98.
What is the Fund Sentiment?
There are 318 funds or institutions reporting positions in Spyre Therapeutics. This is an increase of 7 owner(s) or 2.25% in the last quarter. Average portfolio weight of all funds dedicated to SYRE is 0.11%, an increase of 7.92%. Total shares owned by institutions increased in the last three months by 0.81% to 71,590K shares. 
The put/call ratio of SYRE is 1.67, indicating a bearish outlook.
What are Other Shareholders Doing?
Fairmount Funds Management holds 4,018K shares representing 5.18% ownership of the company. No change in the last quarter.
Rtw Investments holds 3,622K shares representing 4.67% ownership of the company. No change in the last quarter.
Tang Capital Management holds 3,200K shares representing 4.12% ownership of the company. No change in the last quarter.
SMCWX - SMALLCAP WORLD FUND INC holds 2,743K shares representing 3.54% ownership of the company. No change in the last quarter.
VR Adviser holds 2,685K shares representing 3.46% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
